Page 10 - Flipbook

mCSPC

Can be rapidly lethal

Occurs either the de novo (synchronous)/recurrent (metachronous) setting

In those at high risk of disease progression, overall survival with ADT monotherapy

is approximately 3 years

Since 2013, multiple pivotal trials have shown that ADT alone is NOT enough and

patients should receive early intensification beyond ADT either by docetaxel or

novel hormonal agents